Figures & data
Figure 1. Effects of STM on cell vitality
(a) Chemical structure of STM. (b) The target genes of STM were analyzed using the STITCH database. (c) Cell Counting Kit-8 assay was used to determine the viability of ATDC5 cells. (d) The SREBF2 mRNA expression was detected by RT-qPCR. *p < 0.05 and *** p < 0.001 vs. Control; #p < 0.05 and ###p < 0.001 vs. IL-1β.
Figure 2. STM reduces cell damage in IL-1β-induced ATDC5 cells via SREBF2
(a) The SREBF2 protein expression was detected by Western blotting. (b) The SREBF2 mRNA expression was detected by RT-qPCR. (c) The protein levels of IL-6, TNF-α and IL-10 were detected by using Western blotting. (d) The levels of MDA, SOD and GSH were detected by using the corresponding kits. (e) The expression levels of collagen X, MMP13, collagen II and aggrecan were detected by Western blotting. ***p < 0.001 vs. Control; ###p < 0.001 vs. IL-1β; &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. IL-1β+STM+Oe-NC.
Figure 3. STM reduces ferroptosis in IL-1β-induced ATDC5 cells via SREBF2
(a) The iron content in cells was detected using an iron colorimetric assay kit. (b) The expression levels of TFR1, ACSL4, GPX4 and SLC7A11 were detected by using Western blotting. (c) The semi-quantitative results of the expression levels of TFR1, ACSL4, GPX4 and SLC7A11. ***p < 0.001 vs. Control; ##p < 0.01 and ###p < 0.001 vs. IL-1β; &p < 0.05, &&p < 0.01 and &&&p < 0.001 vs. IL-1β+STM+Oe-NC.
Figure 4. STM enhances the inhibition of the ferroptosis inhibitor in IL-1β-induced ATDC5 cells
(a) The protein levels of IL-6, TNF-α and IL-10 were detected by using Western blotting. (b) The levels of MDA, SOD and GSH were detected by using the corresponding kits. (c) The expression levels of collagen X, MMP13, collagen II and aggrecan were detected by Western blotting. ***p < 0.001 vs. Control; #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. IL-1β; &p < 0.05 and &&p < 0.01 vs. IL-1β+Fer-1.
